On February 11th women discussed the commercial appeal of Endo’s Xiaflex to treat cellulite. Xiaflex could become the first non-surgical treatment for cellulite, which could be considered transformational. It raised the question, “Would big pharma be interested in investing in Endo or Xiaflex before the product spikes in value?”
Ralph Baker of Shocking The Street and Torian Mitchell (AYCE Network) discussed (1) Endo’s potential as an acquisition target and (2) which pharmaceutical companies would be most-likely to make a play for the company. The experts decided Endo’s most-likely suitor is not who analysts and investors would think of first.
Video On Demand
Twitter Share Code
Facebook Share Code